These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 8377594)

  • 1. Remission of active diabetic hepatitis after correction of hyperglycemia.
    Tak PP; ten Kate FJ
    Liver; 1993 Aug; 13(4):183-7. PubMed ID: 8377594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical, cellular, and physiologic effects of glyburide in non-insulin-dependent diabetes mellitus.
    Olefsky JM
    Am J Med; 1985 Sep; 79(3B):109-12. PubMed ID: 3931458
    [No Abstract]   [Full Text] [Related]  

  • 3. Review of glyburide after one year on the market.
    Feldman JM
    Am J Med; 1985 Sep; 79(3B):102-8. PubMed ID: 3931457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Failure of glyburide and insulin treatment to decrease leucine flux in obese type II diabetic patients.
    Welle S; Nair KS
    Int J Obes; 1990 Aug; 14(8):701-10. PubMed ID: 2121656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal evaluation of the effects of sulfonylurea therapy in subjects with type II diabetes mellitus.
    Kolterman OG
    Am J Med; 1985 Sep; 79(3B):23-33. PubMed ID: 3931459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peppermint essential oil alleviates hyperglycemia caused by streptozotocin- nicotinamide-induced type 2 diabetes in rats.
    Abdellatief SA; Beheiry RR; El-Mandrawy SAM
    Biomed Pharmacother; 2017 Nov; 95():990-999. PubMed ID: 28922713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy of insulin plus oral agent in the elderly diabetic.
    Kyllästinen M
    J Am Geriatr Soc; 1988 Mar; 36(3):286. PubMed ID: 3123544
    [No Abstract]   [Full Text] [Related]  

  • 8. Correction of fasting hyperglycaemia with insulin or sulphonylurea lowers fasting ketone levels, but does not alter resting or post-glucose energy expenditure in non insulin dependent diabetes. Differences between the OGTT and the glucose clamp.
    Boyd K; Boreham C; Andrews WJ; Hadden DR
    Diabetes Res; 1991 Nov; 18(3):101-8. PubMed ID: 1841819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New modalities in diabetes treatment.
    Lawrence AM; Abraira C
    Am J Med; 1988 Nov; 85(5A):153-8. PubMed ID: 3143264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of metformin in type II diabetes.
    Epstein S
    Cleve Clin J Med; 1995; 62(5):278-9. PubMed ID: 7586481
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of a sulfonylurea and insulin on energy expenditure in type II diabetes mellitus.
    Welle S; Nair KS; Lockwood D
    J Clin Endocrinol Metab; 1988 Mar; 66(3):593-7. PubMed ID: 3127418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Combination therapy with insulin/sulfonylurea in the long-term therapy of type II diabetes following "secondary failure"].
    Lotz N; Bachmann W; Ladik T; Mehnert H
    Klin Wochenschr; 1988 Nov; 66(21):1079-84. PubMed ID: 3148787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Partial recovery of insulin secretion and action after combined insulin-sulfonylurea treatment in type 2 (non-insulin-dependent) diabetic patients with secondary failure to oral agents.
    Del Prato S; Vigili de Kreutzenberg S; Riccio A; Maifreni L; Duner E; Lisato G; Iavicoli M; Tiengo A
    Diabetologia; 1990 Nov; 33(11):688-95. PubMed ID: 2127573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Steatosis and cirrhosis secondary to insulin resistance in children. Possible physiopathological mechanisms].
    Bonet Serra B; Barrio Merino A; Quintanar Rioja A; Alavés Buforn M; Nevado Santos M
    An Esp Pediatr; 2002 Apr; 56(4):353-6. PubMed ID: 11927081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of hyperglycemia in adult-onset diabetes mellitus].
    Yki-Järvinen H
    Duodecim; 1999; 115(10):1155-64. PubMed ID: 11877855
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice.
    Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Li Q; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
    Eur J Pharmacol; 2013 Sep; 715(1-3):246-55. PubMed ID: 23707905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maximal dose glyburide therapy in markedly symptomatic patients with type 2 diabetes: a new use for an old friend.
    Peters AL; Davidson MB
    J Clin Endocrinol Metab; 1996 Jul; 81(7):2423-7. PubMed ID: 8675555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response of regimens of insulin therapy in type 2 diabetes mellitus subjects with secondary failure.
    Zargar AH; Masoodi SR; Laway BA; Wani AI; Bashir MI
    J Assoc Physicians India; 2002 May; 50(5):641-6. PubMed ID: 12186116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus.
    Groop L; Widén E; Franssila-Kallunki A; Ekstrand A; Saloranta C; Schalin C; Eriksson J
    Diabetologia; 1989 Aug; 32(8):599-605. PubMed ID: 2506091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined glyburide and insulin therapy in type II diabetes.
    Reich A; Abraira C; Lawrence AM
    Diabetes Res; 1987 Oct; 6(2):99-104. PubMed ID: 3123116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.